13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001969764
Total reported value
$191.1M
$191.1M
28 檔
56.9%
As reported in its official Q1 2024 Form 13F filing, Propel Bio Management, LLC's tracked investment portfolio stood at $191.1M with 28 total positions.
During Q1 2024, Propel Bio Management, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including APLT, HIGH, TCRX) accounted for 56.9% of total reported equity market value during Q1 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | APLT | Applied Therapeutics Inc | Stock-Other | 24.19% | — | +13.71% | |
| 2 | HIGH | Simplify Enhanced Income ETF | ETF-Other | 16.29% | — | +1141.53% | |
| 3 | TCRX | Tscan Therapeutics Inc | Stock-Other | 9.65% | — | — | |
| 4 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 6.69% | — | +43.29% | |
| 5 | ACHV | Achieve Life Sciences Inc | Stock-Other | 6.49% | +6.62% | — | |
| 6 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 5.38% | +0.06% | +96.35% | |
| 7 | AKRO | Akero Therapeutics Inc | Stock-Other | 4.82% | — | +227.58% | |
| 8 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 4.12% | — | — | |
| 9 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 2.65% | — | — | |
| 10 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 2.60% | — | — | |
| 11 | ARDX | Ardelyx Inc | Stock-Other | 2.52% | — | — | |
| 12 | ✓ | Athira Pharma Inc | Stock-Other | 2.38% | — | — | |
| 13 | KURA | Kura Oncology Inc | Stock-Other | 1.61% | — | — | |
| 14 | TSAT | Telesat CORP | Stock-Other | 1.46% | — | — | |
| 15 | KYMR | Kymera Therapeutics Inc | Stock-Other | 1.32% | — | — | |
| 16 | MBB | Ishares Mbs ETF | ETF-Other | 1.20% | — | — | |
| 17 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.15% | — | — | |
| 18 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 1.02% | — | — | |
| 19 | MRNS* | Marinus Pharmaceuticals Inc | Stock-Other | 0.95% | — | — | |
| 20 | KYN | Kayne Anderson Energy Infra | Stock-Other | 0.86% | — | — | |
| 21 | STRO | Sutro Biopharma, Inc. | Stock-Other | 0.64% | — | — | |
| 22 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.52% | -1.67% | EXIT | |
| 23 | ASNSUSD | X4 Pharmaceuticals Inc | Stock-Other | 0.43% | — | — | |
| 24 | 72C | Eiger Biopharmaceuticals Inc | Stock-Other | 0.43% | — | — | |
| 25 | LQD | Ishr Ibx Usd Invgd Cb Etf-ui | ETF-Corp Bonds | 0.28% | — | — | |
| 26 | CYBNEUR | Cybin Inc | Stock-Other | 0.20% | — | — | |
| 27 | ✓ | Fidelity Inv Mmtrsy 1 680 | Stock-Other | 0.12% | — | -95.57% | |
| 28 | ✓ | Chinook Therapeutics Cvr | Stock-Other | 0.02% | — | — |
According to official SEC Form 13F filings, Propel Bio Management, LLC reported a total U.S. public equity portfolio value of $191.1M across 28 disclosed positions in Q1 2024.
During Q1 2024, Propel Bio Management, LLC's top holdings by market value included APLT (24.2%)、HIGH (16.3%)、TCRX (9.7%). The largest single position, APLT, represented 24.2% of total portfolio value.
In Q1 2024, Propel Bio Management, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.